Ad hoc releases are announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
View Featured news and Pulse updates.
Header
Newsroom
Showing 1846 results
December 2017
-
Press release
Novartis announces Oncology head to retire
Basel, December 15, 2017 - Novartis announced today that Bruno Strigini, CEO Novartis Oncology has decided to retire from Novartis and the industry for personal reasons. Joseph Jimenez, CEO of… -
Press release
Novartis gibt Rücktritt des Onkologie-Chefs bekannt
Basel, 15. Dezember 2017 - Novartis gibt bekannt, dass sich Bruno Strigini, CEO Novartis Onkologie, entschieden hat, die Firma aus persönlichen Gründen zu verlassen und sich aus der Industrie… -
Press release
Novartis drug crizanlizumab shown to prolong time to patients' first sickle cell pain crisis in subgroup analysis of SUSTAIN study
Investigational therapy crizanlizumab (SEG101, formerly SelG1) approximately doubled the time to first on-treatment sickle cell pain crisis, according to new subgroup analysis of Phase II SUSTAIN… -
Press release
Primary analysis results from Novartis pivotal JULIET trial show Kymriah(TM) (tisagenlecleucel) sustained complete responses at six months in adults with r/r DLBCL, a difficult-to-treat cancer
At six months, 30% of patients treated with Kymriah were in complete response, with a 74% relapse-free rate after onset of response; median duration of response was not reached Grade 3/4… -
Story Access to Healthcare
Pioneering business approach expands healthcare in Indian villages
Healthy Family program combines health education with improved access to doctors and medicines.
-
Story Patient Perspectives
One boy’s quest to battle cancer
After a diagnosis of childhood cancer, Ryan faced the diagnosis and treatment of leukemia head- on with the support of his family and community.
-
Press release
Sandoz announces new Phase I data showing proposed biosimilar pegfilgrastim matches reference medicine
Phase I study demonstrates matching pharmacokinetic (PK), pharmacodynamic (PD), safety and immunogenicity profiles of Sandoz biosimilar pegfilgrastim and reference medicine Pegfilgrastim is a… -
Press release
Novartis tender offer for Advanced Accelerator Applications commences
Basel, December 7, 2017 -Novartis AG (NYSE: NVS) ("Novartis") today announced that its direct and indirect subsidiary, Novartis Groupe France S.A., a société anonyme organized under the laws of… -
Press release
Kisqali® first and only CDK4/6 inhibitor to show superior efficacy vs. oral endocrine therapy as 1L treatment in randomized Phase III trial in premenopausal women with HR+/HER2- advanced breast cancer
Kisqali plus an oral endocrine partner demonstrated significant efficacy with sustained benefit of nearly two years (median PFS 23.8 vs 13.0 months for endocrine therapy alone) and… -
Story Discovery
Researchers overcome hurdles to test experimental malaria drug
The race is on to find a new treatment before resistance to today’s drugs becomes widespread.
November 2017
-
Featured News
Exploring the future of access to healthcare in lower-income countries
The third Novartis Social Business stakeholder dialogue took place on November 21 in Basel. -
Press release
Novartis' Cosentyx® is first biologic to show long-term efficacy in nail and palmoplantar psoriasis, which can impact up to 90% of psoriasis patients
Unique Cosentyx® (secukinumab) data reinforce treatment option for up to 90% of psoriasis patients who may develop nail or palmoplantar psoriasis[1]-[4] Cosentyx results represent the first data…